D. Z. Du

Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer

Emer O. Hanrahan, Heather Lin, Edward S. Kim et al. · Journal of Clinical Oncology · 2009 · 131 citations · Full text

Medicine, Oncology, Pharmacology +17

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Amado J. Zurita, Eric Jonasch, X Wang et al. · Annals of Oncology · 2011 · 128 citations · Full text

Medicine, Cancer Biology, Oncology +16

Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC)

Emer O. Hanrahan, Huann‐shyang Lin, D. Z. Du et al. · Journal of Clinical Oncology · 2007 · 10 citations

Medicine, Oncology, Pharmacology +17